Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Human CellExp GCSFR /CD114, human recombinant protein
CSF3R, CD114, GCSFR
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q99062 |
|---|---|
| Calculated MW | This protein is fused with 6×his tag at the N-terminus, has a calculated MW of 69 kDa expressed. The predicted N-terminus is Glu 25. Protein migrates as 94 kDa in reduced SDS-PAGE resulting from glycosylation. |
| Gene ID | 1441 |
|---|---|
| Gene Symbol | GCSFR |
| Other Names | CSF3R, CD114, GCSFR |
| Gene Source | Human |
| Source | HEK293 cells |
| Assay&Purity | SDS-PAGE; ≥95% |
| Assay2&Purity2 | N/A; |
| Recombinant | Yes |
| Results | Measured by its ability to inhibit the GCSF-induced proliferation of NFS-60 mouse myeloid cells. The ED50 for this effect is typically 0.02-2 µg /ml in the presence of 0.125 ng /ml of recombinant human GCSF. |
| Target/Specificity | GCSFR /CD114 |
| Application Notes | Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C. |
| Format | Lyophilized |
| Storage | -20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Granulocyte Colony Stimulating Factor Receptor (G-CSFR), also known as Cluster of Differentiation 114 (CD114), CSF3R and GCSF, is a cell-surface receptor for the granulocyte colony-stimulating factor (G-CSF), a cytokine that plays a critical role in the regulation of the activation, proliferation, differentiation, and survival of the neutrophilic granulocyte lineage. G-CSFR belongs to a family of cytokine receptors known as the hematopoietin receptor family. This type I membrane protein has a composite structure consisting of an immunoglobulin(Ig)-like domain, a cytokine receptor-homologous (CRH) domain and three fibronectin type I?II (FNIII) domains in the extracellular region. G-CSFR is present mainly on precursor cells in the bone marrow, and, in response to stimulation by G-CSF, initiates cell proliferation and differentiation into mature neutrophilic granulocytes and macrophages. G-CSFR mediates the specific effect of GCSF through activating a variety of intracellular signaling cascades, including the Jak/Stat, PI3/Akt, Ras-Raf-MAP kinase, and Src family kinase pathways, and thus functions in defense against infection, inflammation and repair, and in the maintenance of steady state hematopoiesis. Mutations in this gene are a cause of Kostmann syndrome, also known as severe congenital neutropenia. Mutations in the intracellular part of this receptor are also associated with certain types of leukemia.
References
Larsen A.,et al.J. Exp. Med. 172:1559-1570(1990).
Fukunaga R.,et al.Proc. Natl. Acad. Sci. U.S.A. 87:8702-8706(1990).
Seto Y.,et al.J. Immunol. 148:259-266(1992).
Haniu M.,et al.Arch. Biochem. Biophys. 324:344-356(1995).
Fukunaga R.,et al.EMBO J. 10:2855-2865(1991).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
